[{"address1": "770 Lindaro Street", "city": "San Rafael", "state": "CA", "zip": "94901", "country": "United States", "phone": "415 506 6700", "website": "https://www.biomarin.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "BioMarin Pharmaceutical Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. It has license and collaboration agreements with Sarepta Therapeutics; Ares Trading S.A.; Catalyst Pharmaceutical Partners, Inc.; and CAMP4 Therapeutics Corporation. The company was incorporated in 1996 and is headquartered in San Rafael, California.", "fullTimeEmployees": 3401, "companyOfficers": [{"maxAge": 1, "name": "Mr. Alexander  Hardy", "age": 54, "title": "President, CEO & Director", "yearBorn": 1969, "fiscalYear": 2023, "totalPay": 1715598, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Brian R. Mueller", "age": 49, "title": "CFO & Executive VP", "yearBorn": 1974, "fiscalYear": 2023, "totalPay": 1074819, "exercisedValue": 2474925, "unexercisedValue": 1185108}, {"maxAge": 1, "name": "Dr. C. Greg Guyer Ph.D.", "age": 61, "title": "Executive VP & CTO", "yearBorn": 1962, "fiscalYear": 2023, "totalPay": 1114215, "exercisedValue": 0, "unexercisedValue": 876749}, {"maxAge": 1, "name": "Dr. Henry J. Fuchs M.D., Ph.D.", "age": 65, "title": "Advisor", "yearBorn": 1958, "fiscalYear": 2023, "totalPay": 1411725, "exercisedValue": 0, "unexercisedValue": 3725258}, {"maxAge": 1, "name": "Ms. Erin  Burkhart", "age": 44, "title": "Group VP & Chief Accounting Officer", "yearBorn": 1979, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Kevin  Eggan Ph.D.", "title": "Chief Scientific Officer & Senior VP of Research and Early Development", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Traci  McCarty", "title": "Group Vice President of Investor Relations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. George Eric Davis", "age": 52, "title": "Executive VP, Chief Legal Officer, General Counsel & Secretary", "yearBorn": 1971, "fiscalYear": 2023, "totalPay": 1231702, "exercisedValue": 2113615, "unexercisedValue": 4885664}, {"maxAge": 1, "name": "Ms. Humaira  Serajuddin", "title": "Senior VP & Chief Marketing Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Amy  Wireman", "title": "Executive VP & Chief People Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 4, "boardRisk": 2, "compensationRisk": 5, "shareHolderRightsRisk": 5, "overallRisk": 3, "governanceEpochDate": 1730073600, "compensationAsOfEpochDate": 1703980800, "irWebsite": "http://investors.bmrn.com/index.cfm", "maxAge": 86400, "priceHint": 2, "previousClose": 69.91, "open": 68.65, "dayLow": 65.78, "dayHigh": 68.7826, "regularMarketPreviousClose": 69.91, "regularMarketOpen": 68.65, "regularMarketDayLow": 65.78, "regularMarketDayHigh": 68.7826, "trailingPE": 40.168674, "forwardPE": 21.235668, "volume": 2782777, "regularMarketVolume": 2782777, "averageVolume": 1785098, "averageVolume10days": 1511800, "averageDailyVolume10Day": 1511800, "bid": 66.6, "ask": 66.7, "bidSize": 100, "askSize": 200, "marketCap": 12706141184, "fiftyTwoWeekLow": 65.78, "fiftyTwoWeekHigh": 99.56, "priceToSalesTrailing12Months": 4.6157002, "fiftyDayAverage": 76.1084, "twoHundredDayAverage": 83.1292, "currency": "USD", "enterpriseValue": 12370318336, "profitMargins": 0.11708, "floatShares": 179147360, "sharesOutstanding": 190554000, "sharesShort": 5593590, "sharesShortPriorMonth": 6006124, "sharesShortPreviousMonthDate": 1726185600, "dateShortInterest": 1728950400, "sharesPercentSharesOut": 0.0294, "heldPercentInsiders": 0.00885, "heldPercentInstitutions": 1.00689, "shortRatio": 2.64, "shortPercentOfFloat": 0.0296, "impliedSharesOutstanding": 199634000, "bookValue": 28.409, "priceToBook": 2.3471434, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "earningsQuarterlyGrowth": 1.627, "netIncomeToCommon": 322291008, "trailingEps": 1.66, "forwardEps": 3.14, "pegRatio": 0.73, "enterpriseToRevenue": 4.494, "enterpriseToEbitda": 29.032, "52WeekChange": -0.16304755, "SandP52WeekChange": 0.3464489, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "BMRN", "underlyingSymbol": "BMRN", "shortName": "BioMarin Pharmaceutical Inc.", "longName": "BioMarin Pharmaceutical Inc.", "firstTradeDateEpochUtc": 932995800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "bcd60339-c59b-3a43-af89-b10253407aca", "messageBoardId": "finmb_25605", "gmtOffSetMilliseconds": -14400000, "currentPrice": 66.68, "targetHighPrice": 127.0, "targetLowPrice": 65.0, "targetMeanPrice": 96.91, "targetMedianPrice": 91.37, "recommendationMean": 2.1, "recommendationKey": "buy", "numberOfAnalystOpinions": 26, "totalCash": 930444032, "totalCashPerShare": 4.883, "ebitda": 426088992, "totalDebt": 594627008, "quickRatio": 2.387, "currentRatio": 4.271, "totalRevenue": 2752808960, "debtToEquity": 10.984, "revenuePerShare": 14.529, "returnOnAssets": 0.029979998, "returnOnEquity": 0.06252, "freeCashflow": 155326752, "operatingCashflow": 414696992, "earningsGrowth": 1.604, "revenueGrowth": 0.283, "grossMargins": 0.52354, "ebitdaMargins": 0.15478, "operatingMargins": 0.15272, "financialCurrency": "USD", "trailingPegRatio": 0.4016, "__fetch_time": "2024-10-31"}]